Skip to main content
. 2022 Jan 20;17(1):e0261760. doi: 10.1371/journal.pone.0261760

Fig 2. Changes in cholesterols after switching from TDF to TAF.

Fig 2

A. Changes in T-chol, HDL-c, LDL-c, non-HDL-c, and oxidized LDL-c from pre-TAF to post-TAF administration (6–12 months); n = 69. B. Differences in T-chol, HDL-c, LDL-c, non-HDL-c, and oxidized LDL-c among pre-TDF administration, post-TDF administration, pre-TAF administration, and post-TAF administration (6–12 months); n = 33. The duration of TDF administration was 29.1 ± 8.4 months. TDF, tenofovir-disoproxil-fumarate; TAF, tenofovir alafenamide; T-chol, total cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol. Data are shown as means ± standard deviation for triplicate assays. *P < 0.05 or **P < 0.01.